Advanced Development of Smallpox Therapeutics

天花治疗的先进发展

• 批准号: 7696713
• 金额: $ 957.06万
• 依托单位: SIGA TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7696713
• 关键词: Advanced; Development; Smallpox; Therapeutics

This contract supports the advanced development of ST-246 as a novel therapeutic agent for prevention and post-event therapeutic treatment of smallpox and related orthopoxviruses. This new contract enables the formulation and advanced development of a new ST-246 parenteral drug product as well as new ways to use the existing oral formulation of ST-246 to combat smallpox. Success would significantly enhance the utility of ST-246 and substantially expand the biodefense indications for SIGA's original oral formulation.

该合同支持 ST-246 作为一种新型治疗剂的高级开发，用于天花和相关正痘病毒的预防和事后治疗。这份新合同使新的 ST-246 肠外药物产品的配制和高级开发成为可能，并提供了使用 ST-246 现有口服制剂对抗天花的新方法。成功将显着增强 ST-246 的效用，并大幅扩展 SIGA 原始口服制剂的生物防御适应症。